Background
Methods
Patient selection
Treatment plan
Protocol | Number of patients |
---|---|
2AC60 → 4CMF* | 2 |
2FAC50 → 4CMF* | 1 |
6CMF* → 4AT | 1 |
3FAC50 → 3CMF* | 2 |
4CMF → 2FEC75* | 1 |
2AC60 → 4CMF* | 1 |
2CMF* → 4 AC | 1 |
4AC* → 2CMF | 1 |
Statistical analysis
Results
Patient characteristics
Characteristic | Group A [n = 110] No (%) | Group B [n = 134] No (%) | p value |
---|---|---|---|
Age
| |||
<40 | 31 (28.2%) | 23 (17.2%) | 0.039 |
≥40 | 79 (71.8%) | 111 (82.8%) | |
Menopausal status
| |||
No | 75 (72.8%) | 77 (62.1%) | 0.087 |
Yes | 28 (27.2%) | 47 (37.9%) | |
Side
| |||
Right | 48 (43.6%) | 71 (53%) | 0.146 |
Left | 62 (56.4%) | 63 (47%) | |
Surgery
| |||
Mastectomy (Patey or Halsted) | 89 (80.9%) | 116 (86.6%) | 0.23 |
Conservative | 21 (19.1%) | 18 (13.4%) | |
Histology
| |||
DIC | 99 (94,3%) | 120 (90,9%) | 0.33 |
LIC | 6 (5.7%) | 12 (9.1%) | |
SBR
| |||
I | 6 (5.7%) | 11 (8.5%) | 0.567 |
II | 69 (65.1%) | 87 (66.9%) | |
III | 31 (29.2%) | 32 (24.6%) | |
Hormonal receptors
| |||
ER
| |||
Positive | 77 (72%) | 97 (73.5%) | 0.793 |
Negative | 30 (28%) | 35 (26.5%) | |
PR
| |||
Positive | 61 (57.5%) | 82 (62.1%) | 0.474 |
Negative | 45 (42.5%) | 50 (37.9%) | |
Tumour
| |||
pT1 | 16 (14.7%) | 19 (14.5%) | 0.732 |
pT2 | 62 (56.9%) | 76 (58%) | |
pT3 | 28 (25.7%) | 29 (22.1%) | |
pT4 | 3 (2.8%) | 7 (5.3%) | |
pN, axillary
| |||
pN0 | 20 (18.2%) | 40 (29.9%) | 0.001 |
pN1 | 30 (27.3%) | 42 (31.3%) | |
pN2 | 31 (28.2%) | 42 (31.3%) | |
pN3 | 29 (26.4%) | 10 (7.5%) | |
Breast/thoracic wall irradiation
| |||
Yes | 109 (99.1%) | 124 (92.5%) | 0.014 |
No | 1 (0.9%) | 10 (7.5%) | |
Prophylactic supraclavicular fossa radiotherapy
| |||
Yes | 104 (94.5%) | 127 (94.8%) | 0.936 |
No | 6 (5.5%) | 7 (5.2%) | |
Internal mammary radiotherapy
| |||
Yes | 105 (95.5%) | 128 (95.5%) | 0.98 |
No | 5 (4.5%) | 6 (4.5%) | |
Axillary radiotherapy
| |||
Yes | 18 (16.4%) | 31 (23.1%) | 0.189 |
No | 92 (83.6%) | 103 (76.9%) |
Patients characteristics | Group FEC75 [n = 23] No (%) | Group FAC50 [n = 20] No (%) | Group AC60 [n = 57] No (%) | p value |
---|---|---|---|---|
Age
| ||||
<40 | 8 (34.8%) | 7 (35%) | 14 (24.6%) | 0.53 |
≥40 | 15 (65.2%) | 13 (65%) | 43 (75.4%) | |
Menopausal status
| ||||
No | 20 (90.9%) | 14 (77.8%) | 35 (66%) | 0.075 |
Yes | 2 (9.1%) | 4 (22.2%) | 18 (34%) | |
Side
| ||||
Right | 14 (60.9%) | 7 (35%) | 24 (42.1%) | 0.188 |
Left | 9 (39.1%) | 13 (65%) | 33 (57.9%) | |
Surgery
| ||||
Mastectomy | 5 (21.7%) | 5 (25%) | 8 (14%) | 0.457 |
Conservative | 18 (78.3%) | 15 (75%) | 49 (86%) | |
Histology
| ||||
CCI | 20 (95.2%) | 19 (95%) | 52 (94.5%) | 0.992 |
CLI | 1 (4.8%) | 1 (5%) | 3 (5.5%) | |
SBR
| ||||
I | 0 | 1 (5%) | 4 (7.1%) | 0.31 |
II | 14 (70%) | 10 (50%) | 39 (69.6%) | |
III | 6 (30%) | 9 (45%) | 13 (23.2%) | |
Hormonal receptors
| ||||
ER
| ||||
Positive | 18 (81.8%) | 11 (55%) | 42 (76.4%) | 0.106 |
Negative | 4 (18.2%) | 9 (45%) | 13 (23.6%) | |
PR
| ||||
Positive | 17 (77.3%) | 7 (35%) | 31 (57.4%) | 0.022 |
Negative | 5 (22.7%) | 13 (65%) | 23 (42.6%) | |
Tumour
| ||||
pT1 | 6 (26.1%) | 1 (5%) | 9 (16.1%) | 0.514 |
pT2 | 10 (43.5%) | 13 (65%) | 32 (57.1%) | |
pT3 | 7 (30.4%) | 5 (25%) | 13 (23.2%) | |
pT4 | 0 | 1 (5%) | 2 (3.6%) | |
pN, axillary
| ||||
pN0 | 6 (26.1%) | 3 (15%) | 9 (15.8%) | 0.807 |
pN1 | 4 (17.4%) | 4 (20%) | 15 (26.3%) | |
pN2 | 7 (30.4%) | 5 (25%) | 18 (31.6%%) | |
pN3 | 6 (26.1%) | 8 (40%) | 15 (26.3%%) |
Patients characteristics | Mastectomy [n = 205] No (%) | BCT [n = 39] No (%) | p value |
---|---|---|---|
Age
| |||
<40 | 48 (23.4%) | 6 (15.4%) | 0.268 |
≥40 | 157 (76.6%) | 33 (84.6%) | |
Menopausal status
| |||
No | 129 (67.5%) | 23 (63.9%) | 0.669 |
Yes | 62 (32.5%) | 13 (36.1%) | |
Side
| |||
Right | 48 (43.6%) | 71 (53%) | 0.146 |
Left | 62 (56.4%) | 63 (47%) | |
Histology
| |||
DIC | 183 (91.1%) | 36 (100%) | 0.062 |
LIC | 18 (9%) | 0 | |
SBR
| |||
I | 13 (6.6%) | 4 (10.5%) | 0.53 |
II | 130 (65.7%) | 26 (68.4%) | |
III | 55 (27.8%) | 8 (21.1%) | |
Hormone receptors
| |||
ER
| |||
Positive | 120 (60.3%) | 28 (71.8%) | 0.877 |
Negative | 79 (39.7%) | 11 (28.2%) | |
PR
| |||
Positive | 61 (57.5%) | 23 (59%) | 0.877 |
Negative | 45 (42.5%) | 16 (41%) | |
Tumour
| |||
pT1 | 25 (12.4%) | 10 (25.6%) | 0.003 |
pT2 | 111 (55.2%) | 27 (69.2%) | |
pT3 | 55 (27.4%) | 2 (5.1%) | |
pT4 | 10 (5%) | 0 | |
pN, axillary
| |||
pN0 | 49 (23.9%) | 11 (28.2%) | 0.285 |
pN1 | 57 (27.8%) | 15 (38.5%) | |
pN2 | 63 (30.7%) | 10 (25.6%) | |
pN3 | 36 (17.6%) | 3 (7.7%) | |
Protocol
| |||
Anthracycline | 89 (43.4%) | 21 (53.8%) | 0.23 |
CMF | 116 (56.6%) | 18 (46.2%) | |
Breast/thoracic wall irradiation
| |||
Yes | 194 (94.6%) | 39 (100%) | 0.139 |
No | 11 (5.4%) | 0 | |
Prophylactic supraclavicular fossa radiotherapy
| |||
Yes | 193 (94.1%) | 38 (97.4%) | 0.402 |
No | 12 (5.9%) | 1 (2.6%) | |
Internal mammary radiotherapy
| |||
Yes | 195 (94.1%) | 38 (97.4%) | 0.523 |
No | 10 (5.9%) | 1 (2.6%) | |
Axillary radiotherapy
| |||
Yes | 42 (20.5%) | 7 (17.9%) | 0.717 |
No | 163 (79.5%) | 32 (82.1%) |
Treatment compliance
Toxicity | Group A No (%) | Group B No (%) | p value |
---|---|---|---|
Anemia | |||
Grade I | 35 (32.4%) | 25 (19.2%) | 0.009 |
Grade II | 13 (12%) | 7 (5.4%) | |
Grade III | 2 (1.9%) | 1 (1.3%) | |
Grade IV | 0 | ||
Neutropenia | |||
Grade I | 13 (12%) | 15 (11.5%) | 0.4 |
Grade II | 27 (25%) | 26 (20%) | |
Grade III | 8 (7.4%) | 8 (6.2%) | |
Grade IV | 2 (1.9%) | 0 | |
Thrombopenia | |||
Grade I | 2 (1.9%) | 2 (1.5%) | 0.341 |
Grade II | 2 (1.9%) | 0 | |
Grade III | 1 (0.9%) | 0 | |
Grade IV | 0 | 1 (0.8%) |
Outcomes
Factor | P value |
---|---|
Age: <40 vs ≥ 40 | 0.221 |
SBR: I vs SBR II-III | 0.402 |
HR: positive vs negative | 0.675 |
Tumour: pT1–2 vs pT3–4 | 0.263 |
Lymph node involvement: yes vs no | 0.007 |
Regimen: CMF vs Anthracycline | 0.428 |